Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Supratentorial diffuse low-grade gliomas present a slow macroscopic tumor growth that can be quantified through the measurement of their velocity of diametric expansion. We assessed whether spontaneous velocity of diametric expansion can predict long-term outcomes as a categorical variable and as a continuous predictor. METHODS: A total of 407 adult patients with newly diagnosed supratentorial diffuse low-grade gliomas in adults were studied. RESULTS: The mean spontaneous velocity of diametric expansion before first-line treatment was 5.8 ± 6.3 mm/year. During the follow-up (mean, 86.5 ± 59.4 months), 209 patients presented a malignant transformation, and 87 died. The malignant progression-free survival and the overall survival were significantly longer in cases of slow velocity of diametric expansion (median, 103 and 249 months, respectively) than in cases of fast velocity of diametric expansion (median, 35 and 91 months, respectively; P < .001). In multivariate analyses, spontaneous velocity of diametric expansion as a categorical variable (<4, ≥4 and <8, ≥8 and <12, ≥12 mm/year) was an independent prognostic factor for malignant progression-free survival (P < .001; hazard ratio, 3.87; 95% confidence interval [CI], 2.67-5.52) and for overall survival (P < .001; hazard ratio, 4.62; 95% CI, 2.58-7.97). Velocity of diametric expansion was also an independent prognostic factor for overall survival as a continuous predictor, showing a linear relationship between overall survival and spontaneous velocity of diametric expansion (hazard ratio, 1.09 per one unit increase; 95% CI, 1.06-1.12; P < .001). CONCLUSIONS: Independent of the molecular status, the spontaneous velocity of diametric expansion allows the identification of rapidly growing diffuse low-grade gliomas (at higher risk of worsened evolution) during the pretherapeutic period and without delaying treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“VDE, the rate of change in tumor diameter over time, is an independent predictor of outcome in LGGs [43,44,45].”
From BPC 157 Therapy of Myotendinous Junction Injury in Rats (2025) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Erratum to: The 2007 WHO classification of tumours of the central nervous system
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-156115 · Cited by 4,442
— Tumors of the Central Nervous System
(2013) · Pediatric Radiotherapy Planning and Treatment · doi:10.1201/b14554-7 · Cited by 1,751
GLIOMA EXTENT OF RESECTION AND ITS IMPACT ON PATIENT OUTCOME
Sanai, N., & Berger, M. S. (2008) · Neurosurgery · doi:10.1227/01.neu.0000318159.21731.cf · Cited by 1,328 · cited 7×
“Diffuse low-grade gliomas affect young adults3 and are characterized by a slow tumor growth,4 even in the silent period,5 and a transformation to a higher grade of malignancy, leading to neurological disability and, ultimately, to death.6,7 Early maximal safe resection while preserving eloquent brain areas with use of…”
BackgroundInfluentialSelf-citationRole of extent of resection in the long-term outcome of low-grade hemispheric gliomas
Smith, J. S., Chang, E. F., Lamborn, K. R., Chang, S. M., Prados, M. D., Cha, S., Tihan, T., VandenBerg, S., McDermott, M. W., & Berger, M. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9337 · Cited by 1,283 · cited 9×
“Diffuse low-grade gliomas affect young adults3 and are characterized by a slow tumor growth,4 even in the silent period,5 and a transformation to a higher grade of malignancy, leading to neurological disability and, ultimately, to death.6,7 Early maximal safe resection while preserving eloquent brain areas with use of…”
InfluentialPrognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma
Pignatti, F., van den Bent, M., Curran, D., Debruyne, C., Sylvester, R., Therasse, P., Áfra, D., Cornu, P., Bolla, M., Vecht, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.121 · Cited by 955 · cited 1×
“2 mm over a 3-month period) should be considered as high-risk patients together with those without IDH mutation and those with known risk factors according to Pignatti and Chang scoring systems.(20,27) Because these LGGs share outcomes similar to those of malignant gliomas, treatment modalities should be selected acco…”
Guidelines on management of low‐grade gliomas: report of an EFNS–EANO* Task Force
Soffietti, R., Baumert, B. G., Bello, L., Von Deimling, A., Duffau, H., Frénay, M., Grisold, W., Grant, R., Graus, F., Hoang‐Xuan, K., et al. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03151.x · Cited by 505 · cited 1×
“Early maximal safe resection while preserving eloquent brain areas with use of perioperative functional monitoring is currently considered as the first-line treatment option.(3,8) Indeed, there is a growing trend that the extent of resection is a significant prognostic factor for malignant progression-free survival an…”
Self-citationContinuous growth of mean tumor diameter in a subset of grade II gliomas
Mandonnet, E., Delattre, J., Tanguy, M., Swanson, K. R., Carpentier, A. F., Duffau, H., Cornu, P., Van Effenterre, R., Alvord, E. C., & Capelle, L. (2003) · Annals of Neurology · doi:10.1002/ana.10528 · Cited by 493 · cited 1×
“It has previously been reported that LGGs demonstrate a spontaneous velocity of diametric expansion of 4 mm/year before and after surgical resection.(4,14) Of interest, velocity of diametric expansion changes after oncological treatment can predict outcomes in response to chemotherapy and radiotherapy.”
Self-citationPallud, J., Mandonnet, E., Duffau, H., Kujas, M., Guillevin, R., Galanaud, D., Taillandier, L., & Capelle, L. (2006) · Annals of Neurology · doi:10.1002/ana.20946 · Cited by 250 · cited 8×
“This pioneer study addressed only the prognostic significance on overall survival of velocity of diametric expansion as a categorical variable in a subset of 143 LGGs.6 It appears to be logical that the higher the velocity of diametric expansion is, the worse the outcomes are.”
InfluentialSelf-citationSwanson, K. R., Rockne, R. C., Claridge, J., Chaplain, M. A., Alvord, E. C., & Anderson, A. R. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1399 · Cited by 236 · cited 1×
“Accordingly, cell density in such tumors may not be high enough to generate hypoxic foci triggering neoangiogenesis and may lead to a LGG appearance on pathological examination.(28) Indeed, pathological findings do not exhibit significant differences in the spontaneous velocity of diametric expansion.”
Cited by
Duffau, H., & Taillandier, L. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou153 · Cited by 281
Self-citationYoussef, G., & Miller, J. J. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01040-8 · Cited by 165
Schiff, D., van den Bent, M. J., Vogelbaum, M. A., Wick, W., Miller, C. R., TAPHOORN, M. J. B., Pope, W. B., Brown, P. D., Platten, M., Jalali, R., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz033 · Cited by 140
López, P. D. D., Corrales-García, E. M., Martino, J., Aras, E. L., & Dueñas-Polo, M. T. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1631-4 · Cited by 136
“According to some studies, LGGs grow continuously over time at a steady rate of about 4–5 mm per year [27].”
BackgroundVerburg, N., Koopman, T., Yaqub, M. M., Hoekstra, O. S., Lammertsma, A. A., Barkhof, F., Pouwels, P. J. W., Reijneveld, J. C., Heimans, J. J., Rozemuller, A. J. M., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz180 · Cited by 109
“22,23 Diffuse gliomas can be subclassified using different biomarkers—for example, imaging markers such as enhancement on T1G MRI, histopathological markers like the World Health Organization (WHO) classification, or molecular markers such as isocitrate dehydrogenase (IDH) mutational status.”
Patients with incidental WHO grade II glioma frequently suffer from neuropsychological disturbances
Cochereau, J., Herbet, G., & Duffau, H. (2015) · Acta Neurochirurgica · doi:10.1007/s00701-015-2674-3 · Cited by 102
“tients needed to have undergone at least two MRIs spaced 3 months apart before surgery, demonstrating objective tumor growth using a previously described methodology [31].”
MethodSelf-citationThe management of low-grade gliomas in adults
Morshed, R. A., Young, J. S., Hervey‐Jumper, S. L., & Berger, M. S. (2019) · Journal of Neurosurgical Sciences · doi:10.23736/s0390-5616.19.04701-5 · Cited by 104
Clinical Management of Diffuse Low-Grade Gliomas
Lombardi, G., Barresi, V., Castellano, A., Tabouret, É., Pasqualetti, F., Salvalaggio, A., Cerretti, G., Caccese, M., Padovan, M., Zagonel, V., et al. (2020) · Cancers · doi:10.3390/cancers12103008 · Cited by 86
“Additionally, tumor size measurement using either 2D-FLAIR diameters or three-dimensional FLAIR (3D-FLAIR) volumetry has been shown to increase diagnostic accuracy in LGG follow up, the growth-rate being an early predictor of malignant transformation [28,29].”
MethodLemaitre, A., Herbet, G., Ng, S., Moritz‐Gasser, S., & Duffau, H. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab275 · Cited by 87
Self-citationOverview of prognostic factors in adult gliomas
Sharma, A., & Graber, J. J. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-20-640 · Cited by 70
“The presence of contrast enhancement and rapid change over time has been associated with poorer outcomes (14-16).”
BackgroundIntra-rater variability in low-grade glioma segmentation
Bø, H. K., Solheim, O. S., Jakola, A. S., Kvistad, K.-A., Reinertsen, I., & Berntsen, E. M. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2312-9 · Cited by 72
Ginet, M., Zaragori, T., Marie, P., Roch, V., Gauchotte, G., Rech, F., Blonski, M., Lamiral, Z., Taillandier, L., Imbert, L., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04509-y · Cited by 61
Self-citationEpidemiology and Molecular Epidemiology
Bauchet, L., & Ostrom, Q. T. (2018) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2018.08.010 · Cited by 69
Self-citationZemmoura, I., Fournier, E., El‐Hage, W., Jolly, V., Destrieux, C., & Velut, S. (2015) · Neurosurgery · doi:10.1227/neu.0000000000000993 · Cited by 66
The silent phase of diffuse low-grade gliomas. Is it when we missed the action?
Pallud, J., Capelle, L., Taillandier, L., Badoual, M., Duffau, H., & Mandonnet, E. (2013) · Acta Neurochirurgica · doi:10.1007/s00701-013-1886-7 · Cited by 58
Self-citationGoze, C., Blonski, M., Le Maistre, G., Bauchet, L., Dezamis, E., Page, P., Varlet, P., Capelle, L., Devaux, B., Taillandier, L., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou085 · Cited by 56
“By contrast, IDH1 mutation status has no significant impact on spontaneous VDE.(12,17) Because IDH1 mutations occur at an early stage of the development of LGG(9,18) and are not significantly involved in tumor growth,(17) we hypothesized that spontaneous VDE and IDH1 mutation status are independent predictors of outco…”
BackgroundSelf-citationQuantitative texture analysis in the prediction of IDH status in low-grade gliomas
Jakola, A. S., Zhang, Y., Skjulsvik, A. J., Solheim, O. S., Bø, H. K., Berntsen, E. M., Reinertsen, I., Gulati, S., Förander, P., & Brismar, T. B. (2017) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2017.12.007 · Cited by 57
Diffuse low-grade glioma – Changing concepts in diagnosis and management: A review
Jooma, R., Waqas, M. S., & Khan, I. (2019) · Asian Journal of Neurosurgery · doi:10.4103/ajns.ajns_24_18 · Cited by 65
“which the patient maybe fully functional if the seizures are controlled,[33] and (iii) a transformational stage of 2–3 years”
BackgroundOzair, A., Bhat, V., Alisch, R. S., Khosla, A. A., Kotecha, R. R., Odia, Y., McDermott, M. W., & Ahluwalia, M. S. (2023) · Cancers · doi:10.3390/cancers15041342 · Cited by 55
“Nearly 70% of diffuse LGGs transform into a higher-grade type [26,27].”
BackgroundBogdańska, M., Bodnar, M., Piotrowska, M. J., Murek, M. K., Schucht, P., Beck, J., Martínez‐González, A., & Pérez‐García, V. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179999 · Cited by 51
Lima, G. L. D. O., Dezamis, E., Corns, R. A., Rigaux-Viodé, O., Moritz‐Gasser, S., Roux, A., Duffau, H., & Pallud, J. (2017) · Neurochirurgie · doi:10.1016/j.neuchi.2016.08.007 · Cited by 45
Self-citationCloughesy, T. F., van den Bent, M. J., Touat, M., Blumenthal, D. T., Peters, K. B., Ellingson, B. M., Clarke, J. L., Mendez, J. S., Yust‐Katz, S., Welsh, L. C., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00472-3 · Cited by 58
Muto, J., Dezamis, E., Rigaux-Viodé, O., Peeters, S., Roux, A., Zanello, M., Mellerio, C., Sauvageon, X., Varlet, P., Oppenheim, C., et al. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.01.213 · Cited by 50
Self-citationClinical Presentation, Natural History, and Prognosis of Diffuse Low-Grade Gliomas
Smits, A., & Jakola, A. S. (2018) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2018.08.002 · Cited by 59
de Albuquerque, L. A. F., Almeida, J. P., Filho, L. D. M., Joaquim, A. F., & Duffau, H. (2020) · Neurosurgical Review · doi:10.1007/s10143-020-01362-8 · Cited by 47
Self-citationCochereau, J., Herbet, G., Rigau, V., & Duffau, H. (2015) · Journal of neurosurgery · doi:10.3171/2014.12.jns141851 · Cited by 43
Self-citationImpact of imaging measurements on response assessment in glioblastoma clinical trials
Reardon, D. A., Ballman, K., Buckner, J. C., Chang, S. M., & Ellingson, B. M. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou286 · Cited by 43
Postoperative follow-up for selected diffuse low-grade gliomas with WHO grade III/IV foci
Darlix, A., Rigau, V., Fraisse, J., Gozé, C., Fabbro, M., & Duffau, H. (2020) · Neurology · doi:10.1212/wnl.0000000000008877 · Cited by 44
“The MTD was calculated from the tumor volume as follows: MTD = cube root of the squared volume (3√volume(2)).(15)WhenMRI inDICOM format was not available, printed slides were collected and the MTD Glossary”
MethodResultSelf-citationSomme, F., Bender, L., Namer, I. J., Noël, G., & Bund, C. (2020) · Cancer Imaging · doi:10.1186/s40644-020-00348-5 · Cited by 38
Smits, A., Zetterling, M., Lundin, M., Melin, B. S., Fahlström, M., Grabowska, A., Larsson, E., & Berntsson, S. G. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00137 · Cited by 41
“Sequential magnetic resonance imaging (MRI) studies of DLGG have demonstrated a linear growth in diameter of the bulky tumor mass before first-line treatment (3).”
BackgroundCuccarini, V., Erbetta, A., Farinotti, M., Cuppini, L., Ghielmetti, F., Pollo, B., DiMeco, F., Grisoli, M., Filippini, G., Finocchiaro, G., et al. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1960-5 · Cited by 37
“Though tumour-growth-rate was correlated with survival in LGG [44], as long as stratification of LGG is based on morphology, the clinical management of these”
Age and surgical outcome of low-grade glioma in Sweden
Corell, A., Carstam, L., Smits, A., Henriksson, R., & Jakola, A. S. (2018) · Acta Neurologica Scandinavica · doi:10.1111/ane.12973 · Cited by 45
Freyschlag, C. F., Krieg, S. M., Kerschbaumer, J., Pinggera, D., Forster, M.-T., Cordier, D., Rossi, M., Miceli, G., Roux, A., Reyes, A. F., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2916-3 · Cited by 37
Self-citationThe landscape of postsurgical recurrence patterns in diffuse low-grade gliomas
Ferracci, F.-X., Michaud, K., & Duffau, H. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.04.009 · Cited by 42
Self-citationFrom Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
Sun, X., & Turcan, Ş. (2021) · Cells · doi:10.3390/cells10051225 · Cited by 38
“Although slower growing (at a rate of ~4–5 mm per year [6]), the majority of IDH‐mutant LGGs eventually undergo malignant progression due to activation of the PI3K/mTOR pathway as a result of PTEN loss [7,8] or enhanced PDGF signaling [9].”
BackgroundBhatia, A., Moreno, R., Reiner, A. S., Nandakumar, S., Walch, H. S., Thomas, T. M., Nicklin, P. J., Choi, Y., Skakodub, A., Malani, R., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1180 · Cited by 42
Poulen, G., Gozé, C., Rigau, V., & Duffau, H. (2018) · Journal of neurosurgery · doi:10.3171/2017.10.jns171825 · Cited by 38
Self-citationYang, K., Nath, S., Koziarz, A., Badhiwala, J. H., Ghayur, H., Sourour, M., Catana, D., Nassiri, F., Alotaibi, M. B., Kameda-Smith, M. M., et al. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.08.163 · Cited by 40
Oedema‐based model for diffuse low‐grade gliomas: application to clinical cases under radiotherapy
Badoual, M., Gerin, C., Deroulers, C., Grammaticos, B., Llitjos, J., Oppenheim, C., Varlet, P., & Pallud, J. (2014) · Cell Proliferation · doi:10.1111/cpr.12114 · Cited by 34
Self-citationTumor growth dynamics in serially-imaged low-grade glioma patients
Gui, C., Kosteniuk, S., Lau, J. C., & Megyesi, J. F. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2857-x · Cited by 36
Jakola, A. S., Pedersen, L. K., Skjulsvik, A. J., Myrmel, K., Sjåvik, K., & Solheim, O. S. (2022) · Journal of neurosurgery · doi:10.3171/2022.1.jns212514 · Cited by 40
Izquierdo, C., Barritault, M., Poncet, D., Cartalat‐Carel, S., Joubert, B., Bruna, J., Jouanneau, E., Guyotat, J., Vasiljevic, A., Fenouil, T., et al. (2018) · Neurosurgery · doi:10.1093/neuros/nyy513 · Cited by 35
Self-citationChemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network
Darlix, A., Mandonnet, E., Freyschlag, C. F., Pinggera, D., Forster, M.-T., Voss, M., Steinbach, J., Loughrey, C., Goodden, J., Banna, G., et al. (2019) · Neuro-Oncology Practice · doi:10.1093/nop/npy051 · Cited by 33
Self-citationParadoxes of evidence-based medicine in lower-grade glioma: To treat the tumor or the patient?
Duffau, H. (2018) · Neurology · doi:10.1212/wnl.0000000000006288 · Cited by 35
Self-citationIntraoperative MRI and Maximizing Extent of Resection
Rao, G. (2017) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2017.05.003 · Cited by 30
Radiology reporting of low-grade glioma growth underestimates tumor expansion
Gui, C., Lau, J. C., Kosteniuk, S., Lee, D. H., & Megyesi, J. F. (2019) · Acta Neurochirurgica · doi:10.1007/s00701-018-03783-3 · Cited by 30
‘Low grade glioma’: an update for radiologists
Larsen, J., Wharton, S. B., McKevitt, F. M., Romanowski, C. A. J., Bridgewater, C. H., Zaki, H., & Hoggard, N. (2017) · British Journal of Radiology · doi:10.1259/bjr.20160600 · Cited by 37
Duffau, H. (2021) · Cancers · doi:10.3390/cancers13194759 · Cited by 35
Self-citationTrevisi, G., Roujeau, T., & Duffau, H. (2016) · Child s Nervous System · doi:10.1007/s00381-016-3069-3 · Cited by 30
Self-citationEpidemiology of Diffuse Low Grade Gliomas
Bauchet, L. (2017) · Springer eBooks · doi:10.1007/978-3-319-55466-2_2 · Cited by 30
Self-citationLong-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics
Izquierdo, C., Alentorn, A., Idbaïh, A., Simó, M., Kaloshi, G., Ricard, D., Barritault, M., Meyronet, D., Bruna, J., Honnorat, J., et al. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2677-4 · Cited by 29
Ng, S., & Duffau, H. (2023) · Cancers · doi:10.3390/cancers15143698 · Cited by 34
“, the slope of the mean tumor diameter growth curve extrapolated from consecutive volumetric measurements [71], is correlated with long-term clinical outcomes [72].”
BackgroundSelf-citationRoux, A., Tauziède‐Espariat, A., Zanello, M., Peeters, S., Zah‐Bi, G., Párraga, E., Edjlali, M., Lechapt, E., Shor, N., Bellu, L., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa022 · Cited by 25
Self-citationMandonnet, E., Wager, M., Almairac, F., Baron, M.-H., Blonski, M., Freyschlag, C. F., Barone, F., Fontaine, D., Pallud, J., Hegi, M. E., et al. (2017) · Neuro-Oncology Practice · doi:10.1093/nop/npw031 · Cited by 29
Self-citationThe role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma
de la Fuente, M. I., Touat, M., van den Bent, M. J., Preusser, M., Peters, K. B., Young, R. J., Huang, R. Y., Ellingson, B. M., Capper, D., Phillips, J. J., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae259 · Cited by 31
Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas
Jo, J., van den Bent, M. J., Nabors, B., Wen, P. Y., & Schiff, D. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac031 · Cited by 27
Nakasu, S., & Nakasu, Y. (2022) · Neurologia medico-chirurgica · doi:10.2176/jns-nmc.2021-0313 · Cited by 28
Duffau, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.947933 · Cited by 32
“calculation of growth rate (23, 71)—including in DLGG with foci of MT in the middle of the tumor (72).”
BackgroundSelf-citationLatini, F., Fahlström, M., Hesselager, G., Zetterling, M., & Ryttlefors, M. (2020) · Cancer Medicine · doi:10.1002/cam4.3216 · Cited by 28
Satar, Z., Hotton, G. R., & Samandouras, G. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab101 · Cited by 36
Imaging of gliomas at 1.5 and 3 Tesla - A comparative study
Tselikas, L., Souillard-Scémama, R., Naggara, O. N., Mellerio, C., Varlet, P., Dezamis, E., Dômont, J., Dhermain, F. G., Devaux, B. C., Chrétien, F. C., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou332 · Cited by 20
Self-citationA novel radiological classification system for cerebral gliomas: The Brain-Grid
Latini, F., Fahlström, M., Berntsson, S. G., Larsson, E., Smits, A., & Ryttlefors, M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211243 · Cited by 23
Does Pretreatment Tumor Growth Hold Prognostic Information for Patients with Glioblastoma?
Stensjøen, A. L., Berntsen, E. M., Mikkelsen, V. E., TORP, S. H., Jakola, A. S., Salvesen, Ø. O., & Solheim, O. S. (2017) · World Neurosurgery · doi:10.1016/j.wneu.2017.03.012 · Cited by 20
Contemporary management of low-grade glioma: a paradigm shift in neuro-oncology
Hayhurst, C. (2017) · Practical Neurology · doi:10.1136/practneurol-2017-001604 · Cited by 19
Opoku-Darko, M., Eagles, M. E., Cadieux, M., Isaacs, A. M., & Kelly, J. J. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.08.235 · Cited by 23
A high 18F-FDOPA uptake is associated with a slow growth rate in diffuse Grade II–III gliomas
Isal, S., Gauchotte, G., Rech, F., Blonski, M., Planel, S., Chawki, M. B., Karcher, G., Marie, P., Taillandier, L., & Verger, A. (2017) · British Journal of Radiology · doi:10.1259/bjr.20170803 · Cited by 17
Self-citationAdvancements in predicting outcomes in patients with glioma: a surgical perspective
Jakola, A. S., Sagberg, L. M., Gulati, S., & Solheim, O. S. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1735367 · Cited by 18
Statistical evaluation of manual segmentation of a diffuse low-grade glioma MRI dataset
Abdallah, M. B., Blonski, M., Wantz-Mézières, S., Gaudeau, Y., Taillandier, L., & Moureaux, J.-M. (2016) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc.2016.7591703 · Cited by 16
“It was originally proposed to measure the largest diameters in the 3 spatial planes, D1, D2, D3, and then to extrapolate the volume with the following formula: D1∗D2∗D3/2 [5].”
Self-citationLeclerc, A., Roux, A., Elia, A., Peeters, S., Aboubakr, O., Bedioui, A., Planet, M., Benzakoun, J., Simboli, G. A., Tauziède‐Espariat, A., et al. (2024) · Neurosurgical FOCUS · doi:10.3171/2023.11.focus23648 · Cited by 15
Self-citationBourdillon, P., Hlaihel, C., Guyotat, J., Guilloton, L., Honnorat, J., Ducray, F., & Cotton, F. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1737-x · Cited by 16
“By contrast, VDE, which did not appear to be better than the choline/ creatine ratio in our work, has been considered in other studies as an independent predictive factor of anaplastic transformation [46] and should be considered in further studies, especially if tridimensional volumetric analysis is”
ResultSelf-citationSpitaels, J., Devriendt, D., Sadeghi, N., Luce, S., Witte, O. D., Goldman, S., Mélot, C., & Lefranc, F. (2017) · Oncology Letters · doi:10.3892/ol.2017.6543 · Cited by 14
“As there are common outcomes between LGGs and malignant gliomas, treatment modalities should be selected accordingly, and a 3‑month FU period is preferred (33).”
Riva, M., Lopci, E., Castellano, A., Olivari, L., Gallucci, M., Pessina, F., Fernandes, B., Simonelli, M., Navarria, P., Grimaldi, M., et al. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.02.031 · Cited by 16
de Albuquerque, L. A. F., Filho, L. D. M., Borges, F. S., Pessoa, F. C., Diógenes, G. S., Rocha, C. J. V., Almeida, J. P., & Joaquim, A. F. (2023) · World Neurosurgery · doi:10.1016/j.wneu.2023.06.096 · Cited by 15
Boissonneau, S., & Duffau, H. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1342537 · Cited by 15
“prognostic factor, independent of the molecular status [6].”
BackgroundSelf-citationMalhotra, A. K., Karthikeyan, V., Zabih, V., Landry, A., Bennett, J., Bartels, U. K., Nathan, P. C., Tabori, U. Y., Hawkins, C. E., Das, S., et al. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac168 · Cited by 21
Much debated controversies of diffuse low-grade gliomas
Zadeh, G. M., Khan, O. H., Vogelbaum, M., & Schiff, D. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou368 · Cited by 12
Budia, I., Álvarez-Arenas, A., Woolley, T. E., Calvo, G. F., & Belmonte-Beitia, J. (2019) · Journal of The Royal Society Interface · doi:10.1098/rsif.2019.0665 · Cited by 12
Natural history of de novo high grade glioma: first description of growth parabola
Altieri, R., Hirono, S., Duffau, H., Ducati, A., Fontanella, M. M., Rocca, G. L., Melcarne, A., Panciani, P. P., Spena, G., & Garbossa, D. (2020) · Journal of Neurosurgical Sciences · doi:10.23736/s0390-5616.17.04067-x · Cited by 12
Self-citationCheng, Y., Song, S., Wei, Y., Xu, G., An, Y., Ma, J., Yang, H., Qi, Z., Xiao, X., Bai, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.743655 · Cited by 17
“Glioma characterization using multi-modality imaging could have several clinical benefits (15, 16).”
BackgroundEvidenced-based medicine in glioma: molecular biology is only part of the story
(2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30510-7 · Cited by 12
Maimaiti, A., Aili, Y., Turhon, M., Kadeer, K., Aikelamu, P., Wang, Z., Niu, W., Maimaitili, A., Kasimu, M., Wang, Y., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.844973 · Cited by 11
“Similar results were observed in the CGGA mRNA-seq-325 dataset for the lncRNAs CRNDE, CYTOR and SNHG18. the expression levels of these lncRNAs were strongly correlated with chromosome 1p19q codeletion, IDH mutation status, tumour grade, chemotherapy status and age (<40 and ≥40 years) (p < 0.05) (Supplementary Figures…”
BackgroundInfluentialVerdier, M., Deverdun, J., de Champfleur, N. M., Duffau, H., Lam, P., Santos, T. D., Troalen, T., Maréchal, B., Huelnhagen, T., & Bars, E. L. (2023) · Journal of Neuroradiology · doi:10.1016/j.neurad.2023.05.008 · Cited by 10
Self-citationWen, B., Fu, F., Hu, L., Cai, Q., & Xie, J. (2018) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2018.02.036 · Cited by 11
Rodríguez, C. R., Calvo, G. F., Ramis-Conde, I., & Belmonte-Beitia, J. (2017) · Communications in Nonlinear Science and Numerical Simulation · doi:10.1016/j.cnsns.2017.02.008 · Cited by 11
Rao, C., Jin, J., Lu, J., Wang, C., Wu, Z., Zhu, Z., Tu, M., Su, Z., & Li, Q. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.822735 · Cited by 10
Ng, S., & Duffau, H. (2022) · Neurology · doi:10.1212/wnl.0000000000200523 · Cited by 10
Self-citationDuffau, H. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101621 · Cited by 15
“Indeed, the slope of the mean tumor diameter growth curve is an independent prognostic factor for malignant progression-free survival and for OS as a continuous predictor—that is, showing a linear relationship between OS and growth rate [35].”
BackgroundSelf-citationAltieri, R., Certo, F., Rocca, G. L., Melcarne, A., Garbossa, D., Bianchi, A., Crimi, S., Pluchino, A., Peschillo, S., & Barbagallo, G. M. V. (2020) · Radiology and Oncology · doi:10.2478/raon-2020-0071 · Cited by 9
Taillandier, L., Obara, T., & Duffau, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719014 · Cited by 11
“For example, velocity expansion diameter is not incorporated in trials while it is an independent prognostic marker not correlated to molecular profile (45) and more reliable than 2007 WHO classification to predict OS (46, 47).”
BackgroundSelf-citationEpidemiology of Diffuse Low-Grade Gliomas
Bauchet, L. (2013) · Springer eBooks · doi:10.1007/978-1-4471-2213-5_2 · Cited by 12
Self-citationThe role of surgery in grade II/III oligodendroglial tumors
Thon, N., Kreth, F.-W., & Tonn, J. (2015) · CNS Oncology · doi:10.2217/cns.15.26 · Cited by 11
Patterns of Interaction Between Diffuse Low-Grade Glioma and Pregnancy: An Institutional Case Series
Kavouridis, V. K., Calvachi, P., Cho, C. H., & Smith, T. R. (2021) · World Neurosurgery · doi:10.1016/j.wneu.2021.02.136 · Cited by 8
Demetz, M., Krigers, A., Moser, P. L., Kerschbaumer, J., Thomé, C., & Freyschlag, C. F. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04301-x · Cited by 10
What Have We Learned from Recent Clinical Studies in Low-Grade Gliomas?
Rudà, R., Bruno, F., & Soffietti, R. (2018) · Current Treatment Options in Neurology · doi:10.1007/s11940-018-0516-3 · Cited by 8
Data-Driven Predictive Models of Diffuse Low-Grade Gliomas Under Chemotherapy
Abdallah, M. B., Blonski, M., Wantz-Mézières, S., Gaudeau, Y., Taillandier, L., Moureaux, J.-M., Darlix, A., de Champfleur, N. M., & Duffau, H. (2018) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2018.2834159 · Cited by 8
Self-citationVorasidenib for IDH-mutant grade 2 gliomas: clinical advances and future directions
Pan, Z., Bao, J., & Wei, S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1628195 · Cited by 12
“…which typically grow slowly (annual diameter increase of 4 – 6 mm), volumetric analysis (see General Management Principles) enhances risk evaluation by distinguishing indolent tumors suitable for observation or IDH-targeted therapies from those requiring aggressive treatment (17).”
Advances in molecular and imaging biomarkers in lower-grade gliomas
Pïcca, A., Bruno, F., Nichelli, L., Sanson, M., & Rudà, R. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2285472 · Cited by 8
Hathout, L., Ellingson, B. M., Cloughesy, T. F., & Pope, W. B. (2015) · Oncology Reports · doi:10.3892/or.2015.3926 · Cited by 9
Relevance of two manual tumour volume estimation methods for diffuse low‐grade gliomas
Abdallah, M. B., Blonski, M., Wantz-Mézières, S., Gaudeau, Y., Taillandier, L., & Moureaux, J.-M. (2017) · Healthcare Technology Letters · doi:10.1049/htl.2017.0013 · Cited by 8
Self-citationImaging in low-grade glioma: a guide for neurologists
Larsen, J., Hoggard, N., & McKevitt, F. M. (2017) · Practical Neurology · doi:10.1136/practneurol-2017-001686 · Cited by 7
Metadata
- Authors
- Pallud, J., Blonski, M., Mandonnet, E., Audureau, E., Fontaine, D., Sanai, N., Bauchet, L., Peruzzi, P., Frénay, M., Colin, P., Guillevin, R., Bernier, V., Baron, M.-H., Guyotat, J., Duffau, H., Taillandier, L., & Capelle, L.
- Affiliations
- Barrow Neurological Institute (US)
- Corresponding author
- Pallud, Johan
- ORCID
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-02-07
- Volume
- 15
- Issue
- 5
- Pages
- 595-606
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- PMC
- PMC3635513
- OpenAlex
- W2160995760
- Cited by
- 173
- References
- 33
- Citations by year
- 2026: 5 · 2025: 18 · 2024: 8 · 2023: 12 · 2022: 14 · 2021: 13 · 2020: 17 · 2019: 15 · 2018: 16 · 2017: 24 · 2016: 5 · 2015: 11 · 2014: 11 · 2013: 4
- FWCI
- 5.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neuro-Oncology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- diffuse low-grade glioma, tumor growth rate, malignant transformation, prognostic factors, progression-free survival, overall survival, supratentorial glioma, adult glioma
- MeSH terms
- Adolescent, Adult, Aged, Brain Neoplasms, Female, Follow-Up Studies, Glioma, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Survival Rate, Tumor Burden, Young Adult, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.